ITN085ST (PHARAOH) - A Phase I Trial of Autologous Regulatory T Cell Therapy for Autoimmune Hepatitis

STATEMENT OF WORK (SOW) ITN Clinical Trial: ITN085ST (PHARAOH) - A Phase I Trial of Autologous Regulatory T Cell Therapy for Autoimmune Hepatitis The Subrecipient Investigator has been designated as Mechanistic Protocol Co-Chair for the above referenced Immune Tolerance Network Clinical Trial. As Mechanistic Protocol Co-Chair of this trial, they will have overall responsibility for the conduct of the mechanistic component of the study. The Mechanistic Protocol Co-Chair will also participant in regular SMT calls. The Mechanistic Protocol Co-Chair will work under the guidance of the Immune Tolerance Network members located at BRI, UC San Francisco, and Massachusetts General Hospital.